Cancer BiologyCommunications BiologyPeer-reviewed
RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination
Michael Gruet, Yitao Xu, Lijie An…·Hector C. Keun
This study identifies RAS/PI3K pathway mutations as a biomarker for sensitivity to PARP/NAMPT inhibitor combination therapy in epithelial ovarian cancer.
2 citations